PlantierJForreyAWO'NeillMABlairADChristopherTGCutlerRE.Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay. J Infect Dis1976; 134 (suppl): S323–30.
2.
PriceK.Effect of structural modifications on the biological properties of aminoglycoside antibiotics containing 2-deoxystreptamine. Adv Appl Microbiol1974; 18: 191–307.
3.
KucersABennettN.Streptomycin. In: The use of antibiotics. Philadelphia: J. B. Lippincott, 1975: 177–8.
4.
KlasterskyJNyamubeyaBVandenborreL.Antimicrobial effectiveness of kanamycin, aminosidin, BB-K8, sisomicin, gentamicin and tobramycin combined with carbenicillin or cephalothin against gram-negative rods. J Med Microbiol1974; 7: 465–72.
5.
ReynoldsAVHamilton-MillerJMTBrumfittW.Newer aminoglycosides — amikacin and tobramycin: an in vitro comparison with kanamycin and gentamicin. Br Med J1974; 3: 778–80.
6.
KlasterskyJMeunier-CarpentierFCoppens-KahanLDaneauDPrevostJM.Clinical and bacteriological evaluation of netilmicin in gram-negative infections. Antimicrob Agents Chemother1977; 12: 503–9.
7.
StewartDBodeyGP.In vitro activity of sisomicin, an aminoglycoside antibiotic, against clinical isolates. J Antibiot1975; 28: 149–55.
8.
YoungLSHewittWL.Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrob Agents Chemother1973; 4: 617–25.
9.
BurgerLMSanfordJPZweighaftT.Tobramycin: bacteriological evaluation. Am J Med Sci1973; 265: 135–42.
10.
WeinsteinRJYoungLSHewittWL.Activity of three aminoglycosides and two penicillins against four species of gram-negative bacilli. Antimicrob Agents Chemother1975; 7: 172–8.
11.
KlugeRMStandifordHCTantemBComparative activity of tobramycin and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother1974; 6: 442–6.
12.
LockwoodWLawsonL.Studies on the susceptibility of 150 consecutive clinical isolates of Pseudomonas aeruginosa to tobramycin, gentamicin, colistin, carbenicillin and five other antimicrobials. Antimicrob Agents Chemother1973; 4: 281–4.
13.
PriceKEChisholmDRMisiekMLeitnerFTsaiYH.Microbiological evaluation of BB-K8, a new semisynthetic aminoglycoside. J Antibiot1972; 25: 709–31.
14.
DuncanIPennerJ.Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus, and Providencia species. Can Med Assoc J1975; 113: 29–31.
15.
HoltRNewmanR.Gentamicin in pediatrics; treatment of severe urinary tract infections caused by gram-negative bacilli and of staphylococcal infections. J Infect Dis1971; 124 (suppl): S257–8.
16.
RichardsFMcCallCCoxC.Gentamicin treatment of staphylococcal infections. JAMA1971; 215: 1297–300.
17.
FederspilP.Clinical use of gentamicin in ear, nose and throat infections. J Infect Dis1969; 119: 465–70.
18.
ChambersBPallagrosiA.Gentamicin in the treatment of staphylococcal infections. J Int Med Res1977; 5: 442–9.
19.
FinegoldSMWinfieldMEAronsohnRBHewittWLGuzeLB.Clinical experience with kanamycin. Ann NY Acad Sci1958; 76: 319–47.
20.
BunnPABaltchAKrajnyakO.Clinical experience with kanamycin. Ann NY Acad Sci1958; 76: 109–21.
21.
HirschL.Clinical use of kanamycin in staphylococcal infections. Antibiot Ann1958–1959: 811–2.
22.
MoelleringRCWennerstenCKunzLJ.Emergence of gentamicin resistant bacteria: experience with tobramycin therapy of infections due to gentamicin resistant organisms. J Infect Dis1976; 134 (suppl): S40–9.
23.
GuerrantRLStrausbaughLJWenzelRPHamoryBHSandeMA.Nosocomial bloodstream infections caused by gentamicin resistant gram-negative bacilli. Am J Med1977; 62: 894–901.
24.
WeinsteinMJDrubeCGMossELWaitzJA.Microbiologic studies related to bacterial resistance to gentamicin. J Infect Dis1971; 124 (suppl): S11–7.
25.
HenriADaneauDKlasterskyJ.Emergence of bacterial resistance to gentamicin. Int J Clin Pharmacol1973; 8: 216–21.
26.
KeysTFWashingtonJA.Gentamicin resistant Pseudomonas aeruginosa — Mayo Clinic experience, 1970–1976. Mayo Clin Proc1977; 52: 797–801.
27.
PriceKEDeFuriaMDPursianoTA.Amikacin, an aminoglycoside with marked activity against antibiotic resistant clinical isolates. J Infect Dis1976; 134 (suppl): S249–61.
PriceKEPursianoTADeFuriaMDWrightGE.Activity of BB-K8 (amikacin) against clinical isolates resistant to one or more aminoglycoside antibiotics. Antimicrob Agents Chemother1974; 5: 143–52.
30.
MoelleringRCWennerstenCKunzLJPoitrasJW.Resistance to gentamicin, tobramycin, and amikacin among clinical isolates of bacteria. Am J Med1977; 62: 873–81.
31.
JuaregueLCushingRDLernerAM.Gentamicin/amikacin resistant gram-negative bacilli at Detroit General Hospital, 1975–1976. Am J Med1977; 62: 882–8.
32.
FederspilPSchatzleWTieslerE.Pharmacokinetics and ototoxicity of gentamicin, tobramycin, and amikacin. J Infect Dis1976; 134 (suppl): S200–5.
33.
LuftFC.Netilmicin: a review of toxicity in laboratory animals. J Int Med Res1978; 6: 286–98.
34.
FinegoldS.Toxicity of kanamycin in adults. Ann NY Acad Sci1966; 132: 942–56.
35.
DreisB.Kanamycin toxicity in adults. Ann NY Acad Sci1966; 132: 957–67.
36.
Boston Collaborative Drug Surveillance Program. Drug-induced deafness. JAMA1973; 224: 515–6.
37.
Finitzo-HieberTMcCrackenGHRoeserRJ.Ototoxicity in neonates treated with gentamicin and kanamycin: results of a four-year controlled follow-up. J Pediatr1979; 63: 443–50.
NeuHBendushC.Ototoxicity of tobramycin: a clinical overview. J Infect Dis1976; 134 (suppl): S206–18.
44.
FeeWEVierraVLathropGR.Clinical evaluation of aminoglycoside toxicity: tobramycin versus gentamicin, a preliminary report. J Antimicrob Chemother1978; 4 (suppl): 31–6.
45.
SmithCRLipskyJJLaskinOLDouble-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med1980; 302: 1106–9.
46.
BlackRELauWKWeinsteinRJYoungLSHewittWL.Ototoxicity of amikacin. Antimicrob Agents Chemother1976; 9: 956–61.
47.
LaneAZWrightGEBlairDC.Ototoxicity and nephrotoxicity of amikacin. Am J Med1977; 62: 911–8.
48.
MeyerRDLewisRPCarmaltEDFinegoldSM.Amikacin therapy for serious gram-negative bacillary infections. Ann Intern Med1975; 83: 790–800.
49.
TallyFPLouieTJWeinsteinWMBartlettJGGorbachSL.Amikacin therapy for severe gram-negative sepsis. Ann Intern Med1975; 83: 484–8.
50.
ValdiviesoMFeldRRodriguezVBodeyGP. Amikacin therapy of infections in neutropenic patients. Am J Med Sci1975; 270: 453–63.
51.
TallyFPLouieTJO'KeefeJPGorbachSLBartlettJG.Amikacin therapy for severe gram-negative sepsis: efficacy in infections involving gentamicin resistant organisms. J Infect Dis1976; 134 (suppl): S428–32.
52.
MathiasRGRonaldARGurwithMJClinical evaluation of amikacin in the treatment of infections due to gram-negative aerobic bacilli. J Infect Dis1976; 134 (suppl): S394–401.
53.
SmithCRBaughmanKEdwardsCQRogersJFLietmanPS.Controlled comparison of amikacin and gentamicin. N Engl J Med1977; 296: 349–53.
54.
LauWKYoungLSBlackREComparative efficacy and toxicity of amikacin/carbenicillin versus gentamicin/carbenicillin in leukopenic patients. Am J Med1977; 62: 959–66.
55.
KosekJCMazzeRICousinsMJ.Nephrotoxicity of gentamicin. Lab Invest1974; 30: 48–57.
56.
PatelVLuftFCYumNMPatelBZemanWKleitSA.Enzymuria in gentamicin-induced kidney damage. Antimicrob Agents Chemother1975; 7: 364–9.
57.
LuftFCYumMNWalderPDKleitSA.Gentamicin gradient patterns and morphological changes in human kidneys. Nephron1977; 18: 167–74.
58.
MondorfAWZegelmanMKloseJHudusJBreierJ.Comparative studies on the action of aminoglycosides and cephalosporins on the proximal tubule of the human kidney. J Antimicrob Chemother1978; 4 (suppl A): 53–7.
59.
WellwoodJMSimpsonPMTigheJRThompsonAE.Evidence of gentamicin nephrotoxicity in patients with renal allografts. Br Med J1975; 3: 278–81.
60.
SchentagJJLasezkayGPlautMEJuskoWJCumboTJ.Comparative tissue accumulation of gentamicin and tobramycin in patients. J Antimicrob Chemother1978; 4 (suppl A): 23–30.
61.
EdwardsCQSmithCRBaughmanKLRogersJFLietmanPS.Concentrations of gentamicin and amikacin in human kidneys. Antimicrob Agents Chemother1976; 9: 925–7.
62.
BennettWMHartnettMNCravenRGilbertDNPorterGA.Gentamicin concentrations in blood, urine, and renal tissue of patients with end-stage renal disease. J Lab Clin Med1977; 90: 389–93.
63.
WeltonACarterGGCraigTJBryantHHHerbstDVWalderWG.Comparison of the intrarenal disposition of tobramycin and gentamicin: therapeutic and toxicologic answers. J Antimicrob Chemother1978; 4 (suppl): 13–22.
ZaskeDECipolleRJStrateRJ.Gentamicin dosage requirements: wide inter-patient variations in 242 surgery patients with normal renal function. Surg1980; 87: 164–9.
FanningWLGumpDJickH.Gentamicin and cephalothin-associated rises in blood urea nitrogen. Antimicrob Agents Chemother1976; 10: 80–2.
75.
BodeyGValdiviesoMFeldRRodriguezV.Pharmacology of amikacin in humans. Antimicrob Agents Chemother1974; 5: 508–12.
76.
ClarkeJTLibkeRDRegameyCKirbyWM.Comparative pharmacokinetics of amikacin and kanamycin. Clin Pharmacol Ther1974; 15: 610–6.
77.
CabanaBTaggertJ.Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans. Antimicrob Agents Chemother1973; 3: 478–83.
78.
MeyersBHirschmanS.Pharmacologic studies on tobramycin and comparison with gentamicin. J Clin Pharmacol1972; 12: 321–4.
79.
SimonVKMosingerEUMalerczyV.Pharmacokinetic studies of tobramycin and gentamicin. Antimicrob Agents Chemother1973; 3: 445–50.
80.
RegameyCGordonRDKirbyWM.Comparative pharmacokinetics of tobramycin and gentamicin. Clin Pharmacol Ther1973; 14: 396–403.
81.
LodeHKemmerichBKoeppeP.Comparative clinical pharmacology of gentamicin, sisomicin and tobramycin. Antimicrob Agents Chemother1975; 8: 396–401.
82.
SiberGREcheverriaPSmithALPaisleyJWSmithDH.Pharmacokinetics of gentamicin in children and adults. J Infect Dis1975; 132: 637–51.
83.
OrmeBCutlerR.The relationship between kanamycin pharmacokinetics, distribution and renal function. Clin Pharmacol Ther1969; 10: 543–50.
84.
McHenryMCGavanTLGiffordRWGentamicin dosages for renal insufficiency. Ann Intern Med1971: 74: 192–7.
85.
GingellJWaterworthP.Dose of gentamicin in patients with normal renal function and renal impairment. Br Med J1968; 2: 19–22.
86.
LodeHGrunertKKoeppePLangmaackH.Pharmacokinetics and clinical studies with amikacin, a new amino-glycoside antibiotic. J Infect Dis1976; 134 (suppl): S316–22.
87.
KirbyWMClarkeJTLibkeRDRegameyC.Clinical pharmacology of amikacin and kanamycin. J Infect Dis1976; 134 (suppl): S312–5.
88.
McHenryMCWagnerJGHallPMVidtDGGavanTL.Pharmacokinetics of amikacin in patients with impaired renal function. J Infect Dis1976; 134 (suppl): S343–8.
89.
LumholtzBKampmanJSiersbaek-NielsenKHansenJM.Dose regimen of kanamycin and gentamicin. Acta Med Scand1974; 196: 521–4.
90.
GyselynckAForreyACutlerR.Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J Infect Dis1971; 124 (suppl): S70–6.
91.
GordonRCRegameyCKirbyWM, Serum protein binding of the aminoglycoside antibiotics. Antimicrob Agents Chemother1973; 2: 214–6.
92.
LockwoodWBowerJ.Tobramycin and gentamicin concentration in the serum of normal and anephric patients. Antimicrob Agents Chemother1973: 3: 125–9.
93.
McCloskeyRBeckerG.Evaluation of the Cutler-Orme Method for administration of kanamycin during renal failure. Antimicrob Agents Chemother1970; 10: 161–4.
94.
HalprenBAAxlineSGCoplonNSBrownDM.Clearance of gentamicin during hemodialysis: comparison of four artificial kidneys. J Infect Dis1976; 133: 627–36.
95.
DeRosaRBuoncristianiUCapitanucciPFrogilloRJ.Tobramycin toxicological and pharmacological studies in animals and pharmacokinetics research in patients with varying degrees of renal impairment. J Int Med Res1974; 2: 100–14.
96.
JaffeGMeyersBRHirschmanSZ.Pharmacokinetics of tobramycin in patients with stable renal impairment, patients undergoing peritoneal dialysis. Antimicrob Agents Chemother1974; 5: 611–6.
97.
MadhavanTYarembhukKLevinNEffect of renal failure and dialysis on the serum concentration of the aminoglycoside amikacin. Antimicrob Agents Chemother1976; 10: 464–6.
98.
LevyJKlasterskyJ.Correlation of serum creatinine concentration and amikacin half-life. J Clin Pharmacol1975; 15: 705–7.
99.
HofflerDKoeppePDemersHG.Pharmacokinetics of amikacin for treatment of urinary tract infections in patients with reduced renal function. J Infect Dis1976; 134 (suppl): S369–73.
100.
WelchHWrightWWWeinsteinHIStaffaAW.In vitro and pharmacological studies with kanamycin. Ann NY Acad Sci1958; 76: 66–80.
101.
WhiteAKnightV.Kanamycin: pharmacological, microbiological and clinical observations. Ann NY Acad Sci1958; 76: 277–88.
102.
RodriguezVBodeyGPValdiviesoMFeldR.Clinical pharmacology of sisomicin. Antimicrob Agents Chemother1975; 7: 38–41.
103.
MosegaardAWellingPGMadsenPO.Gentamicin and gentamicin Cl in the treatment of complicated urinary tract infections — comparative study of efficacy, tolerance and pharmacokinetics. Antimicrob Agents Chemother1975; 7: 328–32.
104.
DanishMSchultzRJuskoWJ.Pharmacokinetics of gentamicin and kanamycin during hemodialysis. Antimicrob Agents Chemother1974; 6: 641–7.
105.
AltmannGBogokowskyBBonerGEliahouHE.Blood levels of ampicillin, kanamycin and gentamicin in the uremic patient. Isr J Med Sci1970; 6: 683–90.
106.
ChristopherTGKornDBlairADForreyAWO'NeillMACutlerRE.Gentamicin pharmacokinetics during hemodialysis. Kidney Int1974; 6: 38–44.
107.
Letourneau-SahebLLapierreLDaigneaultRPrud-HommeMSt. LouisGSiroisG.Gentamicin pharmacokinetics during hemodialysis in patients suffering from chronic renal failure. Int J Clin Pharmacol1977; 15: 116–20.
108.
RegeurLColdingHJensenHKampmanJP.Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis. Antimicrob Agents Chemother1977; 11: 214–8.
109.
MeyerRDLewisRPFinegoldSM.Amikacin therapy of serious gram-negative bacillary infections in chronic hemodialysis patients. Chemotherapy1978; 24: 172–8.
110.
AtkinsRMionCDespauxEVan-HaiNJulienCMoinH.Peritoneal transfer of kanamycin and its use in peritoneal dialysis. Kidney Int1973; 5: 391–6.
111.
MalacoffFRFinkelsteinFOAndrioleVT.Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin. Antimicrob Agents Chemother1975; 8: 574–80.
112.
BogerWGavinJ.Kanamycin: its cerebrospinal fluid diffusion, renal clearance and comparison with streptomycin. Antibiot Ann1958–1959: 677–83.
113.
KaiserAMcGeeZ.Aminoglycoside therapy of gram-negative bacillary meningitis. N Engl J Med1975; 293: 1215–20.
114.
RiffLJJacksonGG.Pharmacology of gentamicin in man. J Infect Dis1971; 124 (suppl): S98–105.
115.
RahalJ.Treatment of gram-negative bacillary meningitis in adults. Ann Intern Med1972; 77: 295–302.
116.
BriedisDJRobsonHG.Cerebrospinal fluid penetration of amikacin. Antimicrob Agents Chemother1978; 13: 1042–3.
117.
HewittWFinegoldS.Laboratory studies with kanamycin. Ann NY Acad Sci1958; 76: 122–8.
118.
PrestonF.The excretion of kanamycin in bile and pancreatic fluid. Antibiot Ann1959–1960: 857–61.
119.
KeighleyMRDrysdaleRBQuoraishiAHBurdonDWAlexander-WilliamsJ.Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum. Gut1976; 17: 495–500.
120.
PittHARobertsFBJohnsonWD.Gentamicin levels in the human biliary tract. J Infect Dis1973; 127: 299–302.
121.
HullJHSarubbiFA.Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med1976; 85: 183–9.
SchwartzSNPazinGJLyonJAHoMPasculleAW.A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis1978; 138: 499–505.
124.
HallWHGerdingDNSchierlEA.Penetration of tobramycin into infected extravascular fluids and its therapeutic effectiveness. J Infect Dis1977; 135: 957–61.
125.
DeeTHKozinF.Gentamicin and tobramycin penetration into synovial fluid. Antimicrob Agents Chemother1977; 12: 548.
126.
KampmanJSiersbek-NielsenKKristensenMHansenJM.Rapid evaluation of creatinine clearance. Acta Med Scand1974; 196: 517–20.
127.
KahlmeterGKammeC.Prolonged excretion of gentamicin in a patient with unimpaired renal function. Lancet1975; 1: 286.
128.
SchentagJJJuskoWJPlautMECumboTJVanceJWAbrutynE.Tissue persistence of gentamicin in man. JAMA1977; 238: 327–9.
129.
KahlmeterGJonssonSKammeC.Longstanding post-therapeutic gentamicin serum and urine concentrations in patients with unimpaired renal function: a pharmacokinetic evaluation. J Antimicrob Chemother1978; 4: 145–52.
130.
WalkerBGentryL.A randomized comparative study of tobramycin and gentamicin in the treatment of complicated urinary tract infections. J Infect Dis1976; 134 (suppl): S146–9.
131.
DoughertyL.Kanamycin in genitourinary tract infections. Antibiot Ann1958–1959: 713–20.
132.
GeddesA.The treatment of serious gram-negative infections with kanamycin. Postgrad Med J1967; 43 (suppl): 44–6.
133.
KootaGMSchweinburgFBRutenburgAM.Role of kanamycin in the management of infections. N Engl J Med1960; 263: 629–33.
134.
RutenbergA.Status of kanamycin in the treatment of surgical infections. Ann NY Acad Sci1966; 132: 824–33.
135.
MadsenPOKjaerTBMosegaardA.Comparison of tobramycin and gentamicin in the treatment of complicated urinary tract infections. J Infect Dis1976; 134 (suppl): S150–2.
136.
ChristenssonPEkbergMDennebergT.Gentamicin in acute and chronic pyelonephritis. Acta Path Microbiol Scand1973;sect B81 (suppl 241): 69–72.
137.
GoodingPGBermanELaneAZAgreK.A review of results of clinical trials with amikacin. J Infect Dis1976; 134 (suppl): S441–5.
138.
MurdochJ.Clinical experiences with kanamycin in septicemia caused by gram-negative organisms. Ann NY Acad Sci1966; 132: 842–9.
139.
BodeyGPMiddlemanEUmsawasdiTRodriguezV.Intravenous gentamicin therapy for infections in patients with cancer. J Infect Dis1971; 124 (suppl): S174–9.
140.
BodeyGPMiddlemanEUmsawasdiTRodriguezV.Infections in cancer patients. Cancer1972; 29: 1697–701.
141.
McHenryMCGavinTLVan OmmenRAHawkWA.Therapy with gentamicin for bacteremic infections: results with 53 patients. J Infect Dis1971; 124 (suppl): S164, 73.
142.
CoxCHarrisonL.Comparison of gentamicin and polymixin B-kanamycin therapy of bacteremia due to gram-negative bacilli. J Infect Dis1971; 124 (suppl): S156–63.
143.
StoneHKolbL.Gentamicin sulfate in the treatment of extra-urinary infections due to gram-negative bacteria. South Med J1967; 60: 142–4.
144.
JaffeGRaverbyWMeyersBRHirschmanSZ.Clinical study of the use of the new aminoglycoside tobramycin for therapy of infections due to gram-negative bacteria. Antimicrob Agents Chemother1974; 5: 75–81.
145.
TallyFGorbachS.Review of 152 patients with bacteremias treated with amikacin. Am J Med1977; 62: 940–4.
146.
LouriaDBYoungLArmstrongDSmithJ.Gentamicin in the treatment of pulmonary infections. J Infect Dis1969; 119: 483–5.
147.
GatmaitanBGCarruthersMMLernerAM.Gentamicin in the treatment of primary gram-negative pneumonias. Am J Med Sci1970; 260: 90–4.
148.
Van Der StraetenMPauwelsRPijckJVan NimmenLKluyskensPSoepH.Amikacin in the treatment of gram-negative bronchopulmonary infections. J Infect Dis1976; 134 (suppl): S391–3.
149.
TrenholmeGMMcKellarPPReveraNLevinS.Amikacin in the treatment of gram-negative pneumonia. Am J Med1977; 62: 949–53.
150.
KlasterskyJHensgensCHenriADaneuD.Comparative clinical study of tobramycin and gentamicin. Antimicrob Agents Chemother1974; 5: 133–8.
151.
SchumacherG.Practical pharmacokinetic techniques for drug consultation and evaluation. Am J Hosp Pharm1975; 32: 299–308.
152.
MawerGELucasSBMcGoughJG.Nomogram for kanamycin dosage. Lancet1972; 2: 45.
153.
MawerGELucasSBKnowlesBRStirlandRM.Computer assisted prescribing of kanamycin for patients with renal insufficiency. Lancet1972; 1: 12–15.
154.
SorenenAWSzaboLPedersenAScharfA.Correlation between renal function and serum half-life of kanamycin and its application to dosage adjustment. Postgrad Med J1967; 43: 37–43.
155.
CutlerROrmeB.Correlation of serum creatinine concentration and kanamycin half-life. JAMA1969; 209: 539–42.
156.
ChanRABennerEJHoeprichPD.Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med1972; 76: 773–8.
CutlerREGyselynckAFleetWPRorreyAM.Correlation of serum creatinine concentration and gentamicin half-life. JAMA1972; 219: 1037–41.
159.
BechtolLBlackH.Tobramycin in renal impairment. Am J Med Sci1975; 269: 317–21.
160.
Nebcin® (tobramycin), product information, Eli Lilly and Co., 1980.
161.
SarubbiFAHullJH.Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med1978; 89: 612–8.
162.
PijckJHallynckTSoepHBaertLDaneelsRBoelaertJ.Pharmacokinetics of amikacin in patients with renal insufficiency, relation of half-life and creatinine clearance. J Infect Dis1976; 134 (suppl): S331–41.
KayeDLevisonMELabovitzED.The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function. J Infect Dis1974; 132: 165–74.
165.
BarzaMBrownRBShenDGibaldiMWeinsteinL.Predictability of gentamicin blood levels in man. J Infect Dis1975; 132: 165–74.
166.
PenningtonJEDaleDCReynoldsHYMacLowryJD.Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. J Infect Dis1975; 132: 270–5.
167.
BarzaMLauermannM.Why monitor serum levels of gentamicin?. Clin Pharmacokinet1978; 3: 202–15.
168.
JacksonGGRiffLJ.Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment of gentamicin. J Infect Dis1971; 124 (suppl): S185–91.
169.
NoonePParsonsTMSlackRCGarfield-DaviesD.Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J1974; 1: 477–81.
170.
DahlgrenJGAndersonETHewittWL.Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother1975; 8: 58–62.
171.
GoodmanEVan GelderJHolmesRHullARSan-FordJP.Prospective comparative study of variable dosage and variable frequency regimens for administration of gentamicin. Antimicrob Agents Chemother1975; 8: 434–8.
